Video

Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Emmanuel S. Antonarakis, MBBCh, professor of oncology, Johns Hopkins Medicine, discusses the design of a randomized phase II study of sipuleucel-T (Sip-T) with or without radium-223 dichloride (Xofigo) in men with asymptomatic bone-metastatic castrate-resistant prostate cancer (mCRPC).

The investigator-initiated, open-label, randomized, multicenter phase II trial looked at 30 patients with mCRPC, making it a small patient population, says Antonarakis. Fifteen patients with mCRPC who were asymptomatic or minimally symptomatic were randomized to receive standard sipuleucel-T alone or sipuleucel-T plus radium-223.

In the combination group, it was a bit logistically challenging, says Antonarakis, because patients started off with radium-223, given once every 4 weeks, per the FDA-approved dose and schedule for that agent. After 2 doses of radium-223, they then received sipuleucel-T, which was given in 3 doses every 2 weeks, adds Antonarakis. Then the patients received the third, fourth, fifth, and sixth dose of radium-223. As such, the sipuleucel-T was sandwiched in between the radium-223 injections, concludes Antonarakis.

Related Videos
Aditya Bardia, MD, MPH, FASCO
Christina S. Baik, MD, MPH
Dana Zakalik, MD
David C. Fisher, MD
Kevin Kalinsky, MD, MS
Alberto Montero, MD, MBA, CPHQ
R. Lor Randall, MD, FACS
Daniel E. Haggstrom, MD
Jairam Krishnamurthy, MD, FACP
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System